Stay Informed
of New Reports
Twitter
Where To Report Waste
Fraud, Abuse, Or Retaliation
Where To Report Waste Fraud, Abuse, Or Retaliation

Evaluation of the DoD Internal Controls Related to Patient Eligibility and Pharmaceutical Management Within the National Capital Region Executive Medicine Services

Submitting OIG: 
Department of Defense OIG
Date Issued: 
Tuesday, January 9, 2024
Agency Reviewed / Investigated: 
Department of Defense
Submitting OIG-Specific Report Number: 
DODIG-2024-044
Location(s): 
Agency-Wide
Type of Report: 
Inspection / Evaluation
Questioned Costs: 
$0
Funds for Better Use: 
$0
Report updated under NDAA 5274: 
No
View Document: 
AttachmentSize
PDF icon DODIG-2024-044Redacted-SECURE.pdf5.06 MB

Related Open Recommendations

Recommendation Number Recommendation Status Significant Recommendation Additional Details
D-2024-2044-DEV0PB-0001-0001.A1 Open No
Rec. A.1: The DoD OIG recommended that the Director of the Defense Health Agency, in coordination with the Walter Reed National Military Medical Center Director, develop policies and procedures for the White House Medical Unit to manage controlled and non-controlled medications, including procurement, storage and inventory, prescribing and dispensing, and disposal.
D-2024-2044-DEV0PB-0001-0002.A2 Open No
Rec. A.2: The DoD OIG recommended that the Assistant Secretary of Defense for Health Affairs, in coordination with the Defense Health Agency and the Service Surgeons General, develop a pharmaceutical oversight plan for the White House Medical Unit. At a minimum, the oversight plan should: a. Designate an organization to have oversight responsibility for the White House Medical Unit. b. Establish procedures the auditor should perform and written verification of corrective actions taken in response to auditor recommendations. c. Reconcile medication inventory counts, including disposition of controlled substance unit doses registered to the White House Medical Unit. d. Justify the purchase of brand name medications in writing, including the quantity. e. Designate the use of specific waste containers for medical disposal that comply with Federal and Service policy.
D-2024-2044-DEV0PB-0002-0001.B1 Open No
Rec. B.1: The DoD OIG recommended that the Director of the Defense Health Agency, in coordination with the White House Medical Unit Director, establish controls for White House patient eligibility within the Military Health System.
D-2024-2044-DEV0PB-0002-0002.B2 Open No
Rec. B.2: The DoD OIG recommended that the Assistant Secretary of Defense for Health Affairs, in coordination with the Defense Health Agency Director and the Service Surgeons General, establish an oversight plan for the White House Medical Unit's eligibility practices.
D-2024-2044-DEV0PB-0003-0001.C1 Open No
Rec. C.1: The DoD OIG recommended that the Defense Health Agency Director develop policy and an oversight plan for executive medicine services that includes eligibility criteria and access to care practices for executive medicine services.
D-2024-2044-DEV0PB-0003-0002.C2 Open No
Rec. C.2: The DoD OIG recommended that the Defense Health Agency Director establish controls form billing and cost recovery for outpatient medical services provided to non‑military senior officials of the U.S. Government, as outlined in 32 Code of Federal Regulations section 108.
Displaying 6 of 6 Recommendations